1.Japan Society of Gynecologic Oncology 2018 guidelines for treatment of uterine body neoplasms
Wataru YAMAGAMI ; Mikio MIKAMI ; Satoru NAGASE ; Tsutomu TABATA ; Yoichi KOBAYASHI ; Masanori KANEUCHI ; Hiroaki KOBAYASHI ; Hidekazu YAMADA ; Kiyoshi HASEGAWA ; Hiroyuki FUJIWARA ; Hidetaka KATABUCHI ; Daisuke AOKI
Journal of Gynecologic Oncology 2020;31(1):18-
2.Japan Society of Gynecologic Oncology 2018 guidelines for treatment of uterine body neoplasms
Wataru YAMAGAMI ; Mikio MIKAMI ; Satoru NAGASE ; Tsutomu TABATA ; Yoichi KOBAYASHI ; Masanori KANEUCHI ; Hiroaki KOBAYASHI ; Hidekazu YAMADA ; Kiyoshi HASEGAWA ; Hiroyuki FUJIWARA ; Hidetaka KATABUCHI ; Daisuke AOKI
Journal of Gynecologic Oncology 2020;31(1):e18-
The Fourth Edition of the Guidelines for Treatment of Uterine Body Neoplasm was published in 2018. These guidelines include 9 chapters: 1. Overview of the guidelines, 2. Initial treatment for endometrial cancer, 3. Postoperative adjuvant therapy for endometrial cancer, 4. Post-treatment surveillance for endometrial cancer, 5. Treatment for advanced or recurrent endometrial cancer, 6. Fertility-sparing therapy, 7. Treatment of uterine carcinosarcoma and uterine sarcoma, 8. Treatment of trophoblastic disease, 9. Document collection; and nine algorithms: 1-3. Initial treatment of endometrial cancer, 4. Postoperative adjuvant treatment for endometrial cancer, 5. Treatment of recurrent endometrial cancer, 6. Fertility-sparing therapy, 7. Treatment for uterine carcinosarcoma, 8. Treatment for uterine sarcoma, 9. Treatment for choriocarcinoma. Each chapter includes overviews and clinical questions, and recommendations, objectives, explanation, and references are provided for each clinical question. This revision has no major changes compared to the 3rd edition, but does have some differences: 1) an explanation of the recommendation decision process and conflict of interest considerations have been added in the overview, 2) nurses, pharmacists and patients participated in creation of the guidelines, in addition to physicians, 3) the approach to evidence collection is listed at the end of the guidelines, and 4) for clinical questions that lack evidence or clinical validation, the opinion of the Guidelines Committee is given as a “Recommendations for tomorrowâ€.
3.A Case of Palliative Radiotherapy for Headache Due to Postoperative Skull Metastasis of Pancreatic Cancer
Kensuke YAMADA ; Mitsuhiro NAKAO ; Koichi YOSHIKAWA ; Hirokazu SADAHIRO ; Masako KARITA ; Yuki MANABE ; Hidekazu TANAKA ; Tomomitsu SATO ; Eishi MIZUTA
Palliative Care Research 2024;19(1):41-46
Introduction: Pancreatic cancer often recurs as local recurrence or peritoneal dissemination, causing severe abdominal and back pain. We report a case of postoperative skull metastasis of pancreatic cancer that caused headache and was treated effectively with radiotherapy. Case: A 67-year-old woman underwent surgery for pancreatic cancer. She had epigastric pain due to local recurrence and peritoneal dissemination, which was controlled with loxoprofen and fentanyl transdermal patch. She had right-sided headache, which gradually increased in intensity, but lacked intracranial hypertension and focal neurological symptoms. Acetaminophen and Goreisan did not provide adequate pain relief. Although CT showed no brain or bone metastasis, MRI showed metastasis in the right frontal bone. Palliative radiotherapy was administered. Subsequently, headache decreased from 7–8/10 to 2–3/10 on the Numerical Rating Scale. Conclusion: Skull metastases in cancer patients may be diagnosed using MRI, even when they remain undetectable by CT.